By Sabela Ojea

Pharmaceutical giant GlaxoSmithKline PLC said Tuesday that its Daprodustat drug has been accepted for review by the U.S. Food and Drug Administration.

The FTSE 100-listed company said that Daprodustat is aimed at potentially treating patients with chronic renal anemia.

GlaxoSmithKline said the FDA has assigned a prescription drug user fee act action date--a deadline to review new drugs--of Feb. 1.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

April 19, 2022 02:27 ET (06:27 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more GSK Charts.